PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

By PVI, PeerView Institute for Medical Education

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

  1. 1.
    Ruben A. Mesa, MD, FACP - A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes
  2. 2.
    Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Taking the Fight to AML: Oncology Nurse Perspectives, Principles, and Practice in an Era of Innovative Therapies
  3. 3.
    Alok A. Khorana, MD, FACP, FASCO / Robert D. McBane, II, MD - Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care and Shared Decision-Making Strategies to Improve Patient Outcomes
  4. 4.
    Suzanne Lentzsch, MD, PhD - A New Treatment Era for Light Chain Amyloidosis: Interprofessional Lessons From a Center of Excellence
  5. 5.
    Gail J. Roboz, MD - Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics
  6. 6.
    Matthew S. Davids, MD, MMSc - Pushing Therapeutic Boundaries in CLL: The Convergence of Targeted Therapy, Novel Combinations, and Precision Medicine in Patient Care
  7. 7.
    William G. Wierda, MD, PhD - New Standards for CLL Care With BTK Inhibitors: Using Evidence to Make Personalized Treatment Choices
  8. 8.
    Nicola Gökbuget, MD - Achieving Therapeutic Innovation in ALL: Insights on Modern Asparaginase Compounds in Pediatric, AYA, and Adult Patients
  1. 9.
    Loren D.M. Pena, MD, PhD - Advancing the Treatment of Pompe Disease: Clinical Updates in Newborn Screening and Enzyme Replacement
  2. 10.
    James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA - Management of Hyperlipidemia in the Family Medicine Setting: Diagnosis, Management, and the Role of Emerging Lipid-Lowering Therapies
  3. 11.
    Steven W. Pipe, MD - Envisioning the Future of Emerging Nonfactor Therapies in Hemophilia A and B: The Art and Science of RNA Interference
  4. 12.
    Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease
  5. 13.
    Professor Kausik Ray - Lower Is Better: Novel Therapeutic Strategies Targeting PCSK9 for Reducing LDL-C Levels in Patients With Hyperlipidemia and ASCVD
  6. 14.
    George L. Bakris, MD - Recognizing and Treating Hyperkalemia in Patients With Heart Failure and/or Chronic Kidney Disease: An Update for Hospitalists
  7. 15.
    Sara M. Tinsley, PhD, APRN, AOCN - Therapeutic Advancements in Myelodysplastic Syndromes: Bridging the Gap Between Patient Safety and Quality Care Through the Latest Science and Evidence-Based Learning in Nursing Practice
  8. 16.
    Cedric "Jamie" Rutland, MD - An Animated Exploration of Chronic Fibrosing Interstitial Lung Disease: From Diagnosis to Management in the Era of Antifibrotic Therapy
  9. 17.
    Brendon M. Stiles, MD - Immunotherapy as a Game-Changer in Multimodal Management of Locally Advanced and Earlier Stages of Lung Cancer
  10. 18.
    Lesley Camille Ballance, MSN, FNP-BC / Amy Goodrich, CRNP / Jill Lozensky, RN, BSN, OCN - Changing Times in DLBCL: Oncology Nurse Insight on the Practicalities of Antibody Therapy
  11. 19.
    Elizabeth A. Raetz, MD / Rachel Rau, MD - Meeting Therapeutic Challenges in Pediatric ALL: Expert Perspectives on the Use of Asparaginase Compounds
  12. 20.
    Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation
  13. 21.
    Amy Goodrich, CRNP - Making Modern Treatment Choices in CLL: Oncology Nurse Insights on the Patient Journey and the New Era of Care
  14. 22.
    Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice
  15. 23.
    Brett Elicker, MD - The Importance of Early Recognition of Interstitial Lung Diseases: Practical Strategies for the Radiologist
  16. 24.
    "Joseph D. Khoury, MD, FCAP - Visualizing Progress for TP53-Mutant AML: A Pathology-Guided Journey Through Diagnostic Principles and Modern Treatment"
  17. 25.
    Elizabeth A. Thiele, MD, PhD - Applying Evidence to Practice: Updated Consensus Recommendations for the Diagnosis, Surveillance, and Management of Tuberous Sclerosis Complex
  18. 26.
    Kurt A. Schalper, MD, PhD / Shanu Modi, MD - HER2 and HER3 Alterations as Therapeutic Targets of Increasing Significance in Solid Tumors: Implications for Pathology and Oncology Practice
  19. 27.
    Karl E. Anderson, MD - Acute Hepatic Porphyria: Disease Diagnosis and Revelations Regarding the Role of siRNA Therapy
  20. 28.
    Dara L. Aisner, MD, PhD / Joshua Bauml, MD / Paul A. VanderLaan, MD, PhD - Precision Decisions in Genomic Testing and Targeted Treatment of NSCLC
  21. 29.
    Naval Daver, MD - Optimizing Care for High-Risk Myeloid Cancers: Interprofessional Team Insights From a Center of Excellence
  22. 30.
    Hossein Borghaei, DO, MS / Sanjay Mukhopadhyay, MD / Jonathan A. Nowak, MD, PhD - The Nuances of Immunotherapy Biomarker Testing in Solid Tumors: Unraveling Complexities and Overcoming Challenges to Improve Outcomes
  23. 31.
    Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science
  24. 32.
    John M. Pagel, MD, PhD / Ian W. Flinn, MD, Ph - DConversations on the New Wave of Innovative Therapy in Follicular Lymphoma: Implications for Personalized Medicine
  25. 33.
    Alexander (Ander) Cohen, MB BS (Hons), MSc, MD, FRACP, FESC - New Insights: How Does Real-World Evidence Influence VTE Management? A Visual Exploration of Real-World Studies of DOACs
  26. 34.
    Minetta C. Liu, MD - Innovative Blood-Based Screening in Cancer Care: State of the Science and Future Opportunities for Accelerating Cancer Diagnoses
  27. 35.
    Roy S. Herbst, MD, PhD & Lecia V. Sequist, MD, MPH - New Milestones and Changing Standards of Care in EGFR-Mutated NSCLC: Expanding the Benefits of Genomic Testing and EGFR-Targeted Therapy to Early-Stage Lung Cancer
  28. 36.
    Khaldoun G. Tarakji, MD, MPH - Adopting Telemedicine and Digital Tools for Nonvalvular Atrial Fibrillation Management and Stroke Prevention
  29. 37.
    Stella Lee, MD - Improving the Management of Chronic Rhinosinusitis With Nasal Polyps: Practical Strategies for Selecting the Right Patients for Targeted Treatment
  30. 38.
    Stephen V. Liu, MD - Changing the Game for Patients With ES-SCLC Through Multidisciplinary Collaboration: Best Practices to Optimize Immunotherapy-Based Approaches and Improve Patient Outcomes
  31. 39.
    Robert Z. Orlowski, MD, PhD / Nina Shah, MD - The Multiple Myeloma Workshop: Exploring the Convergence of Novel Therapeutic Platforms, Cell Therapy, and ASCT
  32. 40.
    Reynold A. Panettieri, Jr., MD - Improving Adherence to Evidence-Based Guidelines for the Diagnosis and Management of COPD: Practical Strategies for the Healthcare Team to Optimize Patient Care
  33. 41.
    Jacob Sands, MD - Selective Inhibition of Oncogenic Transcription and Other Novel Approaches in the Treatment of Small Cell Lung Cancer: An Illustrative Guide to Navigating the Evolving Treatment Landscape and Integrating Latest Treatment Modalities Into Clinical Care
  34. 42.
    Professor Kausik Ray - Mastering the Management of Hyperlipidemia in Statin-Treated or Statin-Intolerant Patients: Recent Treatment Advances for Patients That Remain at High Risk of ASCVD
  35. 43.
    Maria Arcila, MD / Zofia Piotrowska, MD - New Horizons in EGFR-Mutated NSCLC: Broadening the Impact of Precision Testing in the Context of an Expanding Treatment Landscape
  36. 44.
    Mark Crowther, MD, MSc, FRCPC, FRSC - Managing Bleeding Events in Patients Receiving Direct Oral Anticoagulants: When Is It Appropriate to Implement Reversal Strategies in Patients With GI Bleeding?
  37. 45.
    Steven D. Gore, MD - Preparing for Personalized Care in Myelodysplastic Syndromes: Integrating Innovative Treatments Into a Cohesive Patient Care Model
  38. 46.
    John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci - Mapping the New Era in CLL Management: Precision Medicine and Patient Perspectives in Treatment-Naïve and Relapsed Disease
  39. 47.
    Steven M. Horwitz, MD - Precision Medicine in Hematologic Cancers: Lessons for Diagnostic and Treatment Protocols in CD30- and CD123-Expressing Disease
  40. 48.
    Sagar Lonial, MD, FACP / Praneetha Thulasi, MD - Targeting Ocular Toxicity in Multiple Myeloma: Opportunities for Ophthalmology-Oncology Collaboration
  41. 49.
    Ian W. Flinn, MD, PhD / Caron Jacobson, MD / Preetesh Jain, MBBS, MD, DM, PhD -Rewriting Patient Care in Mantle Cell Lymphoma: How Innovative Therapy Is Poised to Challenge Conventional Treatment
  42. 50.
    Professor David I. Marks, MB, MS, FRACP, PhD, FRCPath - Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management

Listen to PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast now.

Listen to PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast in full in the Spotify app